Patent classifications
C07D307/93
METHOD OF AMELIORATING UREMIA
A method of ameliorating symptoms of uremia includes administering a therapeutic agent including beraprost or each isomer constituting beraprost, or a salt thereof as an effective ingredient to an animal belonging to the Family Canidae, wherein an effective dosage is a dosage that does not significantly lower blood pressure.
USE OF PARTHENOLIDE DERIVATIVES AS ANTILEUKEMIC AND CYTOTOXIC AGENTS
The present invention provides compounds of the formula (I)
##STR00001## wherein: X.sub.1, X.sub.2 and X.sub.3 are heteroatoms; R.sub.4, R.sub.5, R.sub.6, R.sub.7, R.sub.3, R.sub.9 and R.sub.10 are independently selected from H, halo, —OH, —NO.sub.2, —CN and optionally substituted aliphatic, cycloalkyl, heterocycloalkyl, aryl or heteroaryl; and Z is optionally substituted C.sub.1-8 straight-chained or branched aliphatic, optionally containing 1 or more double or triple bonds, wherein one or more carbons are optionally replaced by R* wherein R* is optionally substituted cycloalkyl, heterocycloalkyl, aryl or heteroaryl; an amino acid residue, H, —CN, —C(O)—, —C(O)C(O)—, —C(O)NR.sup.1—, —C(O)NR.sup.1NR.sup.2—, —C(O)O—, —OC(O)—, —NR.sup.1CO.sub.2—, —O—, —NR.sup.1C(O)NR.sup.2—, —OC(O)NR.sup.1—, —NR.sup.1NR.sup.2—, —NR.sup.1C(O)—, —S—, —SO—, —SO.sub.2—, —NR.sup.1—, —SO.sub.2NR.sup.1—, —NR.sup.1R.sup.2, or —NR.sup.1SO.sub.2—, wherein R.sup.1 and R.sup.2 are independently selected from H and optionally substituted aliphatic, cycloalkyl, heterocycloalkyl, aryl or heteroaryl; or where R* is NR.sup.1R.sup.2, R.sup.1 and R.sup.2 optionally together with the nitrogen atom form an optionally substituted 5-12 membered ring, said ring optionally comprising 1 or more heteroatoms or a group selected from —CO—, —SO—, —SO.sub.2— and —PO—; or a pharmaceutically acceptable salt, ester or prodrug thereof.
Photoresist composition, compound, and production method thereof
A photoresist composition containing (A) a polymer having a structural unit (I) that includes an acid-labile group, and (I) a compound represented by the following formula (1). In the following formula (1), R.sup.1, R.sup.2, R.sup.3 and R represent a hydrogen atom or a monovalent organic group having 1 to 20 carbon atoms. X represents a single bond, an oxygen atom or —NR.sup.a—. R.sup.a represents a hydrogen atom, a hydroxy group or a monovalent organic group having 1 to 20 carbon atoms, and optionally taken together represents a ring structure by binding with R each other. A.sup.− represents —SO.sub.3.sup.− or —CO.sub.2.sup.−. M.sup.+ represents a monovalent onium cation. ##STR00001##
Photoresist composition, compound, and production method thereof
A photoresist composition containing (A) a polymer having a structural unit (I) that includes an acid-labile group, and (I) a compound represented by the following formula (1). In the following formula (1), R.sup.1, R.sup.2, R.sup.3 and R represent a hydrogen atom or a monovalent organic group having 1 to 20 carbon atoms. X represents a single bond, an oxygen atom or —NR.sup.a—. R.sup.a represents a hydrogen atom, a hydroxy group or a monovalent organic group having 1 to 20 carbon atoms, and optionally taken together represents a ring structure by binding with R each other. A.sup.− represents —SO.sub.3.sup.− or —CO.sub.2.sup.−. M.sup.+ represents a monovalent onium cation. ##STR00001##
POLYCYCLIC COMPOUND AND ORGANIC ELETROLUMINESCENCE DEVICE INCLUDING THE SAME
A polycyclic compound according to an embodiment of the inventive concept is represented by the following Formula 1:
##STR00001##
In Formula 1, Ar.sub.1 and Ar.sub.2 are each independently substituted or unsubstituted aryl group having 6 to 30 carbon atoms for forming a ring, or substituted or unsubstituted heteroaryl group having 2 to 30 carbon atoms for forming a ring, where Ar.sub.1 and Ar.sub.2 may combine with each other to form a ring, and A is represented by the following Formula 2-1 or 2-2:
##STR00002##
POLYCYCLIC COMPOUND AND ORGANIC ELETROLUMINESCENCE DEVICE INCLUDING THE SAME
A polycyclic compound according to an embodiment of the inventive concept is represented by the following Formula 1:
##STR00001##
In Formula 1, Ar.sub.1 and Ar.sub.2 are each independently substituted or unsubstituted aryl group having 6 to 30 carbon atoms for forming a ring, or substituted or unsubstituted heteroaryl group having 2 to 30 carbon atoms for forming a ring, where Ar.sub.1 and Ar.sub.2 may combine with each other to form a ring, and A is represented by the following Formula 2-1 or 2-2:
##STR00002##
Compound and use thereof in synthesis of brivaracetam intermediate and crude drug
The present application provides a compound in formula III, and further provides a use of the compound in the synthesis of a Brivaracetam intermediate and a crude drug, and a synthesis method. A raw material involved in the method of the present application is low in costs and easily available; (R)-4-propyl-dihydrofuran-2-ketone having high optical purity can be prepared; complicated separation and purification steps are avoided; costs are reduced, and the method is more applicable to industrial production. ##STR00001##
Small molecule inhibitors of replication protein A that also act synergistically with cisplatin
Replication protein A (RPA) is a single-strand DNA-binding protein with essential roles in DNA replication, recombination and repair. Small molecule inhibitors (SMIs) with the ability to disrupt RPA binding activity to ssDNA have been identified and assessed using both lung and ovarian cancer cell lines. Lung cancer cell lines demonstrated increased apoptotic cell death following treatment with the SMI MCI13E, with IC50 values of ˜5 μM. The A2780 ovarian cancer cell line and the p53-null lung cancer cell line HI 299 were particularly sensitive to MCI13E treatment with IC.sub.50 values below 3 μM. Sequential treatment with MCI13E and cisplatin resulted in synergism, suggesting that decreasing RPA's DNA binding activity via a SMI may disrupt RPA's role in cell cycle regulation. Thus, RPA SMIs hold the potential to be used as single agent chemotherapeutics or in combination with current chemotherapeutic regimens to increase their efficacy.
COMPOUNDS THAT CAN BE USED IN AN ORGANIC ELECTRONIC DEVICE AS ACTIVE COMPOUNDS
The invention relates to compounds that can be used in an organic electronic device as an active compound, in particular for use in electronic devices. The invention further relates to a method for producing the compounds according to the invention, and to electronic devices comprising same.
METHODS AND SYSTEMS FOR WIRELESS TO POWER LINE COMMUNICATIONS
Methods, systems, and apparatus for monitoring and controlling electronic devices using wired and wireless protocols are disclosed. The systems and apparatus may monitor their environment for signals from electronic devices. The systems and apparatus may take and disambiguate the signals that are received from the devices in their environment to identify the devices and associate control signals with the devices. The systems and apparatus may use communication means to send control signals to the identified electronic devices. Multiple apparatuses or systems may be connected together into networks, including mesh networks, to make for a more robust architecture.